Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor
cells and may slow the growth of ovarian epithelial cancer or primary peritoneal cancer.
PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have
recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer.